Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / VNRX - Volition engages Diagnostic Oncology to conduct studies of Nu.Q cancer tests in US

VNRX - Volition engages Diagnostic Oncology to conduct studies of Nu.Q cancer tests in US

VolitionRX Limited

  • VolitionRx ( NYSE: VNRX ) said it appointed Diagnostic Oncology CRO (DXOCRO) to undertake development and clinical validation studies of its Nu.Q cancer tests portfolio in the U.S.
  • DXOCRO will conduct large-scale finding studies at multiple sites in the U.S. using Volition's Nu.Q NETs and Nu.Q cancer tests to evaluate utility in sepsis and cancer. The trial are aimed at U.S. approval of the products, VNRX said in an Aug. 8 press release.
  • "Through multi-site development studies, they will help us demonstrate how our Nucleosomics technology can directly benefit patients and support our application to the FDA's Breakthrough Devices Program and a Pre-submission anticipated in 2023," said Sharon Ballesteros, U.S. head of Quality and Development Process at Volition.

For further details see:

Volition engages Diagnostic Oncology to conduct studies of Nu.Q cancer tests in US
Stock Information
Company Name: VolitionRX Limited
Stock Symbol: VNRX
Market: NYSE
Website: volition.com
Menu
VNRX VNRX Quote VNRX Short VNRX News VNRX Articles VNRX Message Board
Get VNRX Alerts

News, Short Squeeze, Breakout and More Instantly...